T1	Claim 1638 1724	This result may be due to higher rates of fatigue and gastrointestinal adverse events.
T2	Claim 1337 1637	Compared with CET/placebo, the combination of CET/BRIV worsened time to QoL deterioration for patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer on the PF and GHS scales of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30.
T3	Premise 1141 1336	Clinical adverse events of â‰¥ grade 3 were more common with CET/BRIV than with CET/placebo, including fatigue (25% vs 11%), hypertension, rash, diarrhea, abdominal pain, dehydration, and anorexia.
T4	Premise 1046 1140	A greater percentage of patients on the CET/BRIV arm had PF worsening at 6 weeks (31% vs 17%).
T5	Premise 911 1045	Secondary analysis favored CET/placebo for QOL response on the PF, Cognitive Function, Fatigue, Nausea, Appetite, and Diarrhea scales.
T6	Premise 755 910	The median time to deterioration was 1.6 months versus 1.1 months for GHS (P =.02) and 5.6 months versus 1.7 months for PF (P <.0001) favoring CET/placebo.
R1	Support Arg1:T6 Arg2:T2	
R2	Support Arg1:T5 Arg2:T2	
R3	Partial-Attack Arg1:T1 Arg2:T2	
R4	Support Arg1:T3 Arg2:T1	
